1Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators.A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.N Engl J Med,1998,338:1498.
2Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.N Engl J Med,1998,338:1488.
3The RESTORE Investigators.Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.Circulation,1997,96:1445.
4Topol EJ,Moliterno DJ,Herrmann HC,et al.Comparison of two platelet glycoprotein Ⅱb/Ⅲa inhibitors,tirofiban and abciximab,for the prevention of ischemic events with percutaneous coronary revascularization.N Engl J Med,2001,344:1888.
5Moliterno DJ,Yakubov SJ,DiBattiste PM,et al.Outcome at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement:the TARGET follow-up study.Lancet,2002,360(9350):1888.
6Steinhubl SR,Talley DJ,Braden GA,et al.Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention.Results of the GOLD (AU-Assessing Ultegra) Multicenter Study.Circulation,2001,103(21):2528.
7Goto S,Tamura N,Li M,et al.Different effects of various anti-GPⅡb-Ⅲa agents on shear-induced platelet activation and expression of procoagulant activity.J Thrombosis Haemostasis,2003,1:2022.
8Danzi GB,Sesana M,Capuano,et al.Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention.Int J Cardiol,2006,107(2):241.
9Stone GW,Moliterno DJ,Bertrand M,et al.Impact of clinical syndrome acuity on the differential response to 2 glycoprotein Ⅱb/Ⅲa inhibitors in patients undergoing coronary stenting:the TARGET Trial.Circulation,2002,105:2347.
10Danzi GB,Sesana M,Capuano C,et al.Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.Am J Cardiol,2004,94 (1):35.
3Razakjr OA, Tan HC, Yip WL, et al. Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention. J Interv Cardiol, 2005 , 18:33-37.
4Beeres SL, Oemrawsingh PV, Warda HM, et al. Early administration of abciximab in patients with acute myocardial infarction improves angiographic and clinical outcome after primary angioplasty. Catheter Cardiovasc Interv, 2005, 65 : 478-483.
5Lee CW, Hong MK, Lee JH, et al. Determinants and prognostic significance of spontaneous coronary recanalization in acute myocardial infarction. H Am J Cardiol, 2001, 87: 951-954.
6Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasly in acute myocardial infarction : the PACT trial. PACT investigators.Plasminogen-activator Angioplasly Compatibility Trial. J Am Coll Cardiol, 1999, 34:1954-1962.
7Brodie BR, Stuckey TD, Hansen C, et al. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol, 2000,85:13-18.
8van't Hof AW, Ernst N, de Boer MJ, et al. Facilitation of primary coronary, angioplasty by early start of a glycoprotein 2b/3a inhibitor:resulls of the ongoing tirofiban in myocardial infarction evaluation(On-TIME) trial. Eur Heart J, 2004, 25:837-846.
9Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets ( CLEAR PLATELETS) study. Circulation, 2005, 111 :1153-1159.
10Batchelor WB, Tolleson TR, Huang Y, et al. Randomized COMparison of platelet inhibition with abciximab, tiRotiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes : the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation, 2002, 106 : 1470-1476.
